ArticleERJ open research2023
Nebulised interferon-β1a (SNG001) in hospitalised COVID-19: SPRINTER phase III study.
Article in ERJ open research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Efficacy and safety of nebulized inhalation vs. intramuscular delivery of interferon α1b injection for paediatric patients with viral respiratory diseases: a systematic review and meta-analysis.Frontiers in pediatrics · 2025Pooled it
- Effect of inhaled interferon-β1a on SARS-CoV-2 diversity and evolution.Microbiology spectrum · 2026Trial
- Nebulised interferon beta-1a (SNG001) in the treatment of viral exacerbations of COPD.Respiratory research · 2024Trial
- Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.Drugs · 2026Review
- The protective effect and mechanism of rhIFN-α1b on lung injury in mice infected with H1N1 influenza A virus.Archives of microbiology · 2025Article
- Article
- The common genetic variant rs1278960 determining expression of Interferon-lambda predicts inflammatory response in critically ill COVID-19 patients.Scientific reports · 2025Article
- Hidden in plain sight: the impact of human rhinovirus infection in adults.Respiratory research · 2025Review
- Targeting CD73 and correcting adenosinergic signaling in critically ill patients.Frontiers in pharmacology · 2025Review
- Protective effect of interferon type I on barrier function of human airway epithelium during rhinovirus infections in vitro.Scientific reports · 2024Article
- Evaluation of intranasal TLR2/6 agonist INNA-051: safety, tolerability and proof of pharmacology.ERJ open research · 2024Article
- Immunity and Coagulation in COVID-19.International journal of molecular sciences · 2024Review
- Delayed Mucosal Antiviral Responses Despite Robust Peripheral Inflammation in Fatal COVID-19.The Journal of infectious diseases · 2024Article
- Article
- Harnessing the power of IFN for therapeutic approaches to COVID-19.Journal of virology · 2024Review
- Yin and yang of interferons: lessons from the coronavirus disease 2019 (COVID-19) pandemic.Current opinion in immunology · 2024Review
- Feasibility of home administration of nebulised interferon ß-1a (SNG001) for COVID-19: a remote study.BJGP open · 2023Article
- COVID-19-Omics Report: From Individual Omics Approaches to Precision Medicine.Reports (MDPI) · 2023Review
- Interferons in COVID-19: missed opportunities to prove efficacy in clinical phase III trials?Frontiers in medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 7 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Despite the availability of vaccines and therapies, patients are being hospitalised with coronavirus disease 2019 (COVID-19). Interferon (IFN)-β is a naturally occurring protein that stimulates host immune responses against most viruses, including severe acute respiratory syndrome coronavirus 2. SNG001 is a recombinant IFN-β1a formulation delivered to the lungs Methods: Patients were randomised double-blind to SNG001 (n=309) or placebo (n=314) once daily for 14 days plus standard of care (SoC). The primary objective was to evaluate recovery after administration of SNG001 Results: Median time to hospital discharge was 7.0 and 8.0 days with SNG001 and placebo, respectively (hazard ratio (HR) 1.06 (95% CI 0.89-1.27); p=0.51); time to recovery was 25.0 days in both groups (HR 1.02 (95% CI 0.81-1.28); p=0.89). There were no significant SNG001-placebo differences for the key secondary end-points, with a 25.7% relative risk reduction in progression to severe disease or death (10.7% and 14.4%, respectively; OR 0.71 (95% CI 0.44-1.15); p=0.161). Serious adverse events were reported by 12.6% and 18.2% patients with SNG001 and placebo, respectively. Conclusions: Although the primary objective of the study was not met, SNG001 had a favourable safety profile, and the key secondary end-points analysis suggested that SNG001 may have prevented progression to severe disease.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.